News

Exciting New Developments in Parkinson's Therapy by Energenesis

Exciting New Developments in Parkinson's Therapy by Energenesis

Energenesis Biomedical Showcases ENERGI-F705PD at BIO International 2025

Energenesis Biomedical Co., Ltd. (TWSE: 6657), a pioneering biotechnology company, is set to present its promising therapy, ENERGI-F705PD, at the upcoming BIO International Convention 2025. This significant event will be held from June 16 to June 19, where Energenesis will occupy Booth #1645 within the Taiwan Pavilion. The focus of their participation will be to highlight advancements in their ENERGI Platform and discuss their investigational therapy for Parkinson's disease.

Highlighting Innovative Therapies for Parkinson's Disease

The ENERGI-F705PD is an innovative, oral, sustained-release treatment, designed to target key aspects of Parkinson's disease pathogenesis. This first-in-class therapy aims to offer disease-modifying capabilities by addressing its underlying causes. It is expected that topline results from the Phase I trial involving healthy subjects will be revealed in the near future, marking a significant milestone in the development process.

Key Highlights of ENERGI-F705PD

This groundbreaking therapy has some notable features:

  • It aims to mitigate the aggregation of alpha-synuclein, which is a primary contributor to the progression of Parkinson's disease.
  • The therapy enhances the body’s antioxidant defense systems while promoting dopamine synthesis, which is critical for managing symptoms associated with the condition.
  • Findings from preliminary trials have shown promising results that suggest a potential breakthrough in treating this progressive disorder.

Dr. Han-Min Chen, CEO of Energenesis Biomedical, expressed enthusiasm about presenting the progress on ENERGI-F705PD, emphasizing the high unmet medical needs surrounding Parkinson's disease and the potential impact of their therapeutic approach. Their goal is to share the latest advancements in their research and establish partnerships that could expedite the development of this vital therapy.

Components of ENERGI-F705PD

ENERGI-F705PD operates through a multi-faceted mechanism aimed at enhancing cellular health:

  • Alpha-Synuclein Aggregation Prevention: By boosting ATP levels, ENERGI-F705PD helps stave off the harmful aggregation of misfolded proteins.
  • Increased Antioxidant Production: The therapy optimizes pathways critical for the generation of antioxidants, thereby improving cellular resilience against oxidative stress.
  • Support for Dopamine Production: By enhancing specific enzymatic expressions, ENERGI-F705PD aids the restoration of dopamine levels, which are often diminished in Parkinson's patients.

About Energenesis Biomedical Co., Ltd.

Energenesis Biomedical is a leading force in the field of biopharmaceuticals, with a mission to develop groundbreaking therapies that support cellular energy restoration and activate self-repair mechanisms within the body. The company utilizes advanced small-molecule compounds alongside innovative AI algorithms for drug repurposing, focusing on unmet medical needs across various therapeutic domains, including neurodegenerative disorders.

The Expanding Pipeline of Energenesis Biomedical

The company maintains a robust and diverse pipeline of development projects, which includes:

  • ENERGI-F705PD: A promising oral therapy aimed at treating Parkinson's disease, currently in Phase I trials.
  • ENERGI-F703DFU: A specialized gel for treating diabetic foot ulcers, currently undergoing Phase III clinical trials.
  • ENERGI-F701: A tonic for addressing alopecia, which has successfully completed Phase II trials.
  • ENERGI-F703EB: A cream for the rare condition Epidermolysis Bullosa, receiving notable designation from regulatory bodies, in preparation for Phase II trials.

Frequently Asked Questions

What is ENERGI-F705PD?

ENERGI-F705PD is a novel oral therapy in development for Parkinson's disease designed to modify the disease's progression.

How does ENERGI-F705PD work?

The therapy addresses the underlying causes of Parkinson's by reducing alpha-synuclein aggregation and enhancing antioxidant production.

What phase is ENERGI-F705PD currently in?

ENERGI-F705PD is currently in Phase I clinical trials with topline data expected to be released soon.

Who is the CEO of Energenesis Biomedical?

Dr. Han-Min Chen serves as the CEO of Energenesis Biomedical, leading the company in its innovative pursuits.

What is Energenesis Biomedical's mission?

The mission of Energenesis Biomedical is to develop innovative therapeutics that restore cellular energy and support healing mechanisms in various diseases.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Chattanooga: A New Epicenter for Quantum Computing

Updated Category News Views 1

Quantum Leap: Chattanooga's Bold Move So Chattanooga’s making waves again, folks. EPB just unveiled its new big shot, the IonQ Forte Enterprise quantum computer. That's right, they’ve slapped a commercial quantum computer and a networking hub together, right here in this Tennessee city. Is this a tech haven or what? Not to mention, it’s the first in America. A New...

Continue Reading
California Accelerates AI Law with Newsom's Bold Move

Updated Category News Views 3

Pushing AI Regulations into High Gear I'll tell you what—it's about time somebody shook things up in the AI world with more than empty promises. Governor Newsom's executive order is doing just that, fast-tracking the timeline for implementing California's SB 813. This move is like giving speed boots to the legislative process, revving up the rules to ensure AI doesn't...

Continue Reading
Fly High: Encouraging Girls to Soar into Aviation

Updated Category News Views 2

The Sky's Not the Limit—It's Just the Beginning Step aside, conventional paths. There's a flight school owner in Sedona, Arizona, making waves by encouraging girls to swap their land-bound dreams for sky-high aspirations. This International Girls in Aviation Day, Michelle Smith wants young dreamers to know their possibilities span as wide as the open sky. Defying...

Continue Reading
Menopause Policy Advocacy Takes Center Stage in DC

Updated Category News Views 5

Unlikely Spotlight on Menopause at Capitol Hill If you told me a couple of years back that menopause would become a front-page political issue, I would've laughed. Yet, here we are, with over 125 advocates from 29 states converging on Washington, D.C., demanding legislative action on menopause. Why Menopause Matters in Policy The fact that more than half the population is...

Continue Reading
DAHON's Tech: Crafting Folders That Ride Like Road Bikes

Updated Category News Views 4

The Folding Bike Revolution: More Than Just a Fad You've seen them zipping around—those compact, folding bikes. They're not just for urban commuters looking to save space. Oh no, this is a full-blown cycling revolution we're talking about. DAHON, a name that's been rolling since 1982, has been riding these waves and making strides that others can only dream of. While...

Continue Reading
ETERC's Ele Aims to Revolutionize STEM Education for All

Updated Category News Views 6

The AI Mentor Battleground in Education Ever found yourself wondering how public schools could step up their game without dumping money down the tech rabbit hole? ETERC’s latest push with Ele may just be a game-changer for them. We're not talking about your run-of-the-mill chatbot regurgitating facts from the internet—this is an AI tricked out for personalized...

Continue Reading
AI Ambassadors Rethink Arbitration's Future

Updated Category News Views 5

Navigating the AI Terrain in Arbitration It's 2026 and artificial intelligence isn't just a buzzword anymore; it's reshaping every corner of how disputes get resolved. The American Arbitration Association (AAA) has jumped into the mix, launching an AI Ambassador program to tackle a wave of AI-induced challenges. These aren't just academic exercises—this is a hard-nosed...

Continue Reading
Debt Crisis Looms: Social Security at Risk

Updated Category News Views 4

Debt Reality: A National Concern with Global Implications When it comes to the U.S. federal debt situation, the latest report from the National Seniors Policy Center is lighting a fire like no other, warning us that we're not crying wolf here. We've got fiscal numbers that may not sit well at breakfast. With roughly 67 cents of every new buck Uncle Sam borrows going to...

Continue Reading
Debbie's Dream Foundation Launches 2026 Youth Art Contest

Updated Category News Views 5

Young Artists Called to Inspire a Cancer-Free World What's the first image that pops into your head when you think of a world free from cancer? That's the magic question on deck for this year's Youth Art Contest by Debbie's Dream Foundation. Imaginations are set to run wild as the competition opens its gates to artists under 18, calling for visions splashed across...

Continue Reading
Bascom's Strategic Play on a Dallas Apartment Deal

Updated Category News Views 8

Unpacking Bascom's Jasmine Acquisition In a market that's been more slippery than a greased pig, Bascom Group's move buying up Jasmine Apartments is capturing some eyes. Situated in North Dallas, this 370-unit complex ain't just another brick in the wall—it's Bascom's 42nd entry into Texas, reinforcing their knack for sniffing out deals others might tiptoe around,...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Promising Energy Stocks for Growth in 2023

Updated Category News Views 206

Opportunity in Oversold Energy Stocks In the dynamic world of the energy sector, certain stocks are presenting unique buying opportunities as they become increasingly undervalued. This analysis aims to illuminate the potential for growth among these oversold stocks. Understanding the RSI Indicator The Relative Strength Index (RSI) is a key momentum indicator that helps...

Continue Reading
Taylor Farms and Foodiverse Unite for Salad Operations Growth

Updated Category News Views 191

Key Acquisition by Taylor Farms and Foodiverse Foodiverse will manage all activities for the unified businesses. Taylor Farms and Foodiverse have successfully acquired two production plants that specialize in ready-to-eat salads from Bonduelle's fresh sector in Germany. This acquisition allows Foodiverse to consolidate its operations and enhance its influence in the...

Continue Reading
Fast Fresh Brands Selects USIM for Innovative Media Strategy

Updated Category News Views 174

Fast Fresh Brands Selects USIM as Media Agency of Record Fast Fresh Brands (FFB), known for its health-centric quick-service restaurant concepts such as Bee Healthy Café and Nature's Table, has appointed USIM as its media agency of record. This partnership aims to leverage innovative strategies that will help elevate FFB's brand visibility and reach, connecting with...

Continue Reading
Genmab Highlights Epcoritamab's Promise in Hematology Research

Updated Category News Views 48

Genmab Unveils Epcoritamab Innovations at ASH 2024 At the much-anticipated conference, the 66th Annual Meeting of the American Society of Hematology (ASH), Genmab A/S (Nasdaq: GMAB) showcased its advancements in the development of epcoritamab-bysp (known commercially as EPKINLY®). This revolutionary T-cell engaging bispecific antibody is administered subcutaneously and...

Continue Reading
TScan Therapeutics Secures Funding Surge with Warrant Sale

Updated Category News Views 83

TScan Therapeutics Secures $30 Million Funding TScan Therapeutics has successfully secured a substantial investment of $30 million through the sale of warrants. Jason A. Amello, the Chief Financial Officer of TScan, emphasized the critical role this funding will play in extending the company's financial runway. With these additional gross proceeds, TScan anticipates its...

Continue Reading